

Co-located Session

01

## 2015 TEPIK International Influenza Symposium

### Innovative Vaccines, Therapeutics and Research Networks against Influenza Threats

April 9(Thur), 09:00 ~ 16:15 / Grand Ballroom 103

Vision of the Transgovernmental Enterprise for Pandemic Influenza in Korea (TEPIK) is to ensure the safety of nation and people from the threats of pandemic influenza. TEPIK aims to reinforce the national R&D capability and establish a transgovernmental cooperative system for the security of the public's safety from the influenza pandemic. TEPIK has conducted various R&D projects in preparation for the threats of pandemic influenza, including the development and commercialization of advanced vaccines, therapeutics, and diagnostic technology, establishing a research infrastructure, and providing training/network programs for influenza/vaccine experts. This symposium will provide an excellent forum for delegates to update their knowledge and learn about the latest innovations in the field of vaccines, therapeutics, and research networks against influenza threats.

08:30 ~ 09:00 **Registration**

#### Opening Remarks

**Woo Joo Kim, M.D., Ph.D.**, Chair, Transgovernmental Enterprise for Pandemic Influenza in Korea, Korea

09:00 ~ 09:10 **Congratulatory Remarks**

**Woo-Kyung Kim, M.D.**, Ph.D., President of Korea University Medical Center, Executive Vice President for Medical Affairs of Korea University, Korea

**Byungguk Yang**, Director of Korea Centers for Disease Control and Prevention, Korea

#### SESSION 1. VACCINES & DIAGNOSTICS

09:10 ~ 10:25

Vaccination is the primary strategy used to prevent and control influenza. Current influenza vaccines have shown moderate efficacy, good safety, and acceptable tolerability. However, current influenza vaccines do not meet all medical needs. In this session, development of cell culture influenza vaccine in Korea and influenza vaccine effectiveness will be presented. In addition, development of high performance diagnostics for influenza will be discussed.

SESSION  
CHAIRS

**Woo Joo Kim, M.D.**, Ph.D., Chair, Transgovernmental Enterprise for Pandemic Influenza in Korea, Korea

**Futoshi Shibasaki, M.D., Ph.D.**, Director, Head, Department of Genome Medicine, Project Leader of Molecular, Medical Research Project, Tokyo Metropolitan Institute of Medical Science, Japan

09:10 ~ 09:35

#### Development of Cell Culture-based Influenza Vaccine (SkyCellflu) in Korea

**Hun Kim, Ph.D.**, Vice President, Life Science R&D Center, SK Chemicals, Korea

09:35 ~ 10:00

#### Effectiveness of Influenza Vaccine and Needs for Improvement

**Hee Jin Cheong, M.D.**, Ph.D., Professor, College of Medicine, Korea University, Korea

10:00 ~ 10:25

#### High Performance Diagnostics for Influenza

**Naoki Kajiwara, Ph.D.**, Senior Researcher, Molecular Medical Research Project, Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Japan

10:25 ~ 10:40 Session Break

SESSION 2. THERAPEUTICS

10:40 ~ 12:10

Neuraminidase inhibitors is the current therapeutic regimen for influenza. However, the emergence of resistance against neuraminidase inhibitors is concern. Development of novel strategies for influenza therapy and prophylaxis is required. In this session, monoclonal antibodies as a new class of antivirals for influenza virus will be discussed.

SESSION CHAIR **Mihyein Kim, Ph.D.**, Korea Research Institute of Chemical Technology, Korea

**Keynote Speaker**

10:40 ~ 11:20

**The Basis and Bias of Human Anti-Influenza Antibody Response**

**Wayne Marasco, M.D., Ph.D.**, Professor, Department of Medicine, Harvard medical School, USA

11:20 ~ 11:45

**Development of Universal Therapeutic Anti Influenza mAbs**

**Shin Jae Chang, Ph.D.**, Vice President, Celltrion, Inc., Korea

11:45 ~ 12:10

**FAST Functional Antibody Discovery Technology**

**Byeong Doo Song, Ph.D.**, President, Scripps Korea Antibody, Korea

12:10 ~ 13:40

Lunch

SESSION 3. EAST ASIA INFLUENZA NETWORKS

13:40 ~ 16:15

Asia serves as an 'epicenter' for continuous influenza virus activity. In this session, influenza experts from China, Hong Kong, Japan and Korea will talk and discuss cooperation and collaboration.

SESSION CHAIR **Kyung Hyun Kim, Ph.D.**, Professor, College of Science & Technology, Korea University, Korea

**"Mixing Vessel" for Novel Avian Influenza Viruses**

13:40 ~ 14:05

**George Fu Gao, DVM, Ph.D.**, Director, Professor, Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China

**Dissemination, Divergence and Establishment of H7N9 Influenza Viruses in China**

14:05 ~ 14:30

**Yi Guan, M.D., Ph.D.**, Professor, Director, Centre of Influenza Research, The University of Hong Kong, Hong Kong SAR

**Development of Inactivated Intranasal Influenza Vaccine**

14:30 ~ 14:55

**Hideki Hasegawa, M.D., Ph.D.**, Director, Department of Pathology, National Institute of Infectious Diseases, Japan

14:55 ~ 15:15

Coffee Break

**Korea Influenza Sequence and Epitope Database (KISED); A Current Status and Future Scope for the Asian Networking**

15:15 ~ 15:40

**Gi Soon Kim, Ph.D.**, Medical Officer, Division of Influenza Virus, National institute of Health, Korea Centers for Disease Control and Prevention, Korea

**Evolutionary Forces Shaping the Patterns of Influenza Viral Sequence Variation**

15:40 ~ 16:05

**Yuseob Kim, Ph.D.**, Professor, Department of Life Science, Division of EcoScience, Ewha Womans University, Korea

16:05 ~ 16:15

**Summing-up & Closing**